Research to be published in Science on April 29, 2016 shows how cash-hungry patent trolls are squelching innovation when the American economy depends on it more than ever. What should be done?
The new study, co-authored by Professor Lauren Cohen of Harvard Business School, Professor Umit Gurun of the University of Texas at Dallas, and Dr. Scott Duke Kominers, a Junior Fellow at the Harvard University Society of Fellows, examines the sharp rise in patent litigation in the United States during the past decade, with 2015 marking one of the highest patent lawsuit counts on record.
In theory, the rise in patent litigation could reflect growth in the commercialization of technology and innovation, as lawsuits increase proportionately as more and more companies turn to intellectual property (IP) protection to safeguard their competitive advantages. In reality, however, it’s a very different story. The authors point out that the majority of recent patent litigation has been driven by “nonpracticing entities” (NPEs) – firms that generate no products but instead amass patent portfolios just for the sake of enforcing IP rights.
Cohen, Gurun, and Kominers discuss new, large-sample evidence adding to a growing literature that suggests that NPEs—in particular, large patent aggregators—on average act as “patent trolls,” suing cash-rich firms, seemingly irrespective of actual patent infringement.
Patent trolling has a negative impact on innovation activity at targeted firms. Cohen, Gurun, and Kominers estimate that after settling with NPEs (or losing to them in court), companies on average reduce their research and development (R&D) investment by more than 25 percent. These results, Cohen, Gurun, and Kominers say, indicate a need to change U.S. intellectual property policy, particularly to screen out trolling early in the litigation process.
Although since 2010 the U.S. Congress has considered more than a dozen bills aiming to reduce patent trolling, most of the proposed policy changes focus on after-the-fact punishments for bringing lawsuits that are declared to be frivolous (or “extraordinary”) after court proceedings.
For example, H.R. 9, the “Innovation Act,” which is currently on the docket, provides for mandatory fee-shifting for patent lawsuits that the courts determine are not “reasonably justified.” In reality, however, the average costs of patent litigation are large ($1 million to $4 million) and the process is drawn out. Even with the prospect of post-trial fee shifting, patent litigation targets may thus find it cost-effective and less disruptive to simply settle with NPEs, even in unfounded lawsuits. According to the authors, this is not a sufficient solution.
So what should be done? Cohen, Gurun, and Kominers say that policies should screen out trolling at or before the time of patent assertion. The authors recommend advance review procedures that would provide preliminary evaluation as to whether the plaintiff’s infringement claims are reasonable, and whether the asserted patents are of high quality. Such advance review could cripple trolling, they conclude – pre-litigation review can separate good NPEs (and, more generally, good patent lawsuits) from bad. Legitimate infringement claims will be encouraged, whereas trolling will be screened out. This would greatly benefit innovative companies and help them propel the U.S. economy to greater heights.
The Latest on: Patent Aggregators
[google_news title=”” keyword=”Patent Aggregators” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Patent Aggregators
- Selena Gomez Wears Thigh-High Black Patent Boots for Night Out After Addressing Relationship Statuson September 24, 2023 at 8:31 am
The singer and actress, 31, posted a photo of her rocking a pair of racy patent thigh-high boots on her Instagram Story ahead of a night out on Saturday, following a recent TikTok video where she ...
- How a cash-prize system that phases out patents may lower drug priceson September 21, 2023 at 3:57 pm
Two months ago, Sen. Bernie Sanders (I-Vt.) moved a step closer to an idea he has championed for some time — awarding prizes, instead of patents, for inventing medicines. A measure was passed ...
- Amazon Wants to Keep the Cloud Healthyon September 21, 2023 at 10:00 am
Amazon wants to keep its cloud networks from coming apart at the seams. The company filed a patent for a "network health ...
- Apple seeks patent for an augmented reality windshieldon September 20, 2023 at 2:11 pm
In a U.S. Patent Office filing last week, Apple described a graphical overlay on the glass in front of the driver that would provide information about the real-time environment as well as data ...
- Asus sues Samsung for infringing mobile patents, may take several years to resolveon September 20, 2023 at 11:18 am
Read More. Asus has filed a lawsuit against Samsung over wireless communications patents, claiming a violation of a single patent that covers 4G and 5G smartphones. Similar patent disputes have ...
- Patent Poetry: Patent Term Adjustments in Double-Patenting Determinationson September 18, 2023 at 8:37 am
The Federal Circuit has ruled that when members of a patent family have different expiration dates due to patent term adjustments (PTAs), the earlier-expiring patent family members can be used as ...
- Common Patenting Tactic by Drug Companies May Be Illegal, F.T.C. Sayson September 14, 2023 at 8:58 am
Experts say the exploitation of a loophole in the patent system has contributed to high prices for inhalers. By Rebecca Robbins The Federal Trade Commission on Thursday issued what amounted to a ...
- University Of California System Tops U.S. University List For Most Patentson September 12, 2023 at 5:00 pm
The University of California System ranks first among the top 100 universities in the nation for the most U.S. patents granted for inventions in 2022. The list of Top 100 U.S. Universities Granted ...
- Patents are about to get more enforceableon September 12, 2023 at 2:49 pm
“It is quite likely that you, the reader, have infringed a patent today,” reads the first line of professor Janet Freilich’s recent article in the Virginia Law Review. The millions of ...
- HSBC says this biopharma company can jump 25% despite 'patent cliff'on September 6, 2023 at 8:37 am
Amgen has a promising growth outlook despite facing a "substantial patent cliff," according to HSBC. HSBC initiated coverage on the drug treatment developer with a buy rating. Its price target of ...
via Bing News